[THE INVESTOR] South Korean pharmaceutical company Celltrion has received a patent for dolastatin 10 derivative in Australia which is considered a promising anti-cancer drugs showing potency against breast and liver cancer, the firm said on Oct. 14.

The drug maker was granted the license for the process for preparing dolastatin 10 derivative and anti-cancer agents comprising the same.

“Dolastatin 10 derivative which constitutes CT-P26 is proven to outsmart existing carcinostatis substances in terms of anti-cancer activity for breast, colorectal, lung and stomach cancer,” Celltrion said in a regulatory filing. 



CT-P26 has obtained patents in several countries including Korea, the US and European nations. The pharmaceutical firm is waiting for a license in Japan, China and Canada.

The derivative of dolastatin 10 is already applied to a biobetter of Celltrion’s Herzuma, a biosimilar of Roche’s blockbuster breast cancer treatment Herceptin, the company said.

Celltrion plans to submit Herzuma to the European Medicines Agency this quarter for review.

By Park Han-na (hnpark@heraldcorp.com)